PF-47752 |
CEPOKAB 2% Solución inyectable |
2027-08-04 |
|
Fresenius Kabi Mexico, S.A. de C.V. |
Mexico
|
Xentury Global, Sociedad Anónima |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-48734 |
QUINOFRES 500 mg/100 mL Solución inyectable |
2028-10-27 |
|
Fresenius Kabi Mexico, S.A. de C.V. |
Mexico
|
Xentury Global, Sociedad Anónima |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-38450 |
ZYVOX 2 mg/mL Solución inyectable para infusión |
2026-03-23 |
|
Pfizer AS |
Noruega
|
J.I.Cohen, S.A. |
Agencias J. I. Cohen |
Hospifarmacia, S.A. |
Centro Distribuidor, Sociedad Anónima |
Pfizer Corporation Sucursal Guatemala. |
Droguería Y Farmacia Lanquetin |
Pfizer Zona Franca |
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-23674 |
ZYVOX 2mg/mL. Solucion Inyectable para infusión. |
2006-01-15 |
|
Pharmacia & Upjohn Company |
Noruega
|
Agefinsa (Agencia Farm. Intern., S.A.) |
Americana S.A. |
Bodega Farmacéutica S.A. |
Centro Distribuidor S.A. |
Colon S.A. |
Agencias J.i. Cohen |
Lanquetin S.A. |
Merigal S.A. |
Farmacia Upjohn, S.A. |
|
|
|
|
|
|
|
|
|
|
|
PF-35917 |
EPIRUBICINA CLORHIDRATO Fresenius 10mg/5mL solucion inyectable |
2010-08-26 |
|
Fresenius Kabi Oncology Limited |
India
|
Amicelco |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-36631 |
OXITAN 2 mg/mL Solucion Inyectable |
2010-12-08 |
|
Fresenius Kabi Oncology Limited |
India
|
Amicelco |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-39574 |
Gemcitabina Fresenius Kabi 200 mg y 1 g Polvo liofilizado para Solución inyectable |
2028-05-16 |
|
Fresenius Kabi Oncology Limited |
India
|
Xentury Global, Sociedad Anónima |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-40912 |
BEMOCIN 15 U Liofilizado y Solución Para Uso Parenteral |
2018-07-15 |
|
Fresenius Kabi Oncology Limited |
India
|
Amicelco |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-40791 |
VINELBINE 10 mg /mL Solución Inyectable |
2018-06-24 |
|
Fresenius Kabi Oncology Limited |
India
|
Amicelco |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-43305 |
KEMOCARB 150 mg/15 mL solución inyectable |
2019-07-10 |
|
Fresenius Kabi Oncology Limited |
India
|
Amicelco |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|